Skip to main content

Table 6 Description of the 14 children with virological failure (HIV RNA >1000 copies/mL) after the switch

From: Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial

Number

Country

Arm

HIV-1 subtype

Exposure to prenatal ART, maternal or child PMTCT or postnatal ART via breast milk

HIV RNA at ART initiation (copies/mL)

Mutations at ART initiation

 

HIV RNA at 12- month post-randomisation (copies/mL)

Mutations at failure post-switch

      

NRTI

NNRTI

PI

 

NRTI

NNRTI

PI

1

BF

EFV

CRF02_AG

No exposure

19,900,000

None

None

None

6109

None

K103N

None

2

CI

EFV

CRF02_AG

Exposure to child PMTCT (AZT + sdNVP) and postnatal maternal ART (AZT + 3TC + NVP)

242,757

M184V

K103N

None

2091

M184V

K103N, H221Y

None

3

CI

EFV

CRF02_AG

Exposure to maternal PMTCT (AZT) and to child PMTCT (AZT+ sdNVP)

3,573,953

None

None

None

62,866

None

None

None

4

CI

EFV

CRF02_AG

No exposure

1,321,600

None

None

None

102,417

M184V

K103N

None

5

CI

EFV

CRF02_AG

Exposure to maternal PMTCT (AZT + 3TC + NVP) and to child PMTCT (AZT + sdNVP)

3,459,135

None

None

None

1564

Not amplified

Not amplified

Not amplified

6

CI

EFV

CRF02_AG

Exposure to postnatal maternal ART (AZT + 3TC + NVP)

608,578

None

V90I, V179I

None

21,397

M184V

V90I, V179I, K103N

None

7

CI

EFV

CRF02_AG

Exposure to prenatal maternal ART (AZT + 3TC + NVP) initiated 7 years before delivery

12,466,057

M41L, V108I, M184V, L210W, T215Y

Y181C, P225H

None

61,199

M41L, V108I, M184V, L210W, T215Y, L74I

K101E, Y181C, P225H

None

8

BF

LPV/r

CRF02_AG

Exposure to maternal PMTCT (AZT)

7,780,000

None

None

None

7,920,000

None

None

None

9

BF

LPV/r

URF-GK

Exposure to maternal PMTCT (AZT+3TC+NVP) and to child PMTCT (sdNVP) and to postnatal maternal ART (TDF + 3TC + NVP)

4,720,000

None

K103N

None

261,914

None

K103N, Y181C

None

10

BF

LPV/r

CRF02_AG

Exposure to maternal PMTCT (AZT + 3TC + NVP) and child PMTCT (sdNVP)

56,600,000

None

Y181C

None

25,054

None

Y181C

None

11

CI

LPV/r

CRF02_AG

Exposure to child PMTCT (AZT + sdNVP)

254,456

None

None

None

2603

None

None

None

12

CI

LPV/r

CRF02_AG

No exposure

451,590

None

None

None

67,342

M184V

None

None

13

CI

LPV/r

CRF02_CPX

No exposure

915,685

None

K103N, V90I, K101EK

None

3,879,063

None

K103N, V90I, K101EK

None

14

CI

LPV/r

CRF02_AG

Exposure to maternal PMTCT (unknown) and to postnatal maternal ART (AZT + 3TC + LPV/r)

2,710,000

None

None

None

1848

M184V

K103N

None

  1. ART, Antiretroviral therapy, PMTCT Prevention of mother-to-child-transmission, NRTI Nucleoside reverse transcriptase inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, PI Protease inhibitor, BF Burkina Faso, CI Cote d’Ivoire, EFV Efavirenz, LPV/r Lopinavir-boosted ritonavir, AZT Zidovudine, sdNVP single-dose nevirapine, 3TC Lamivudine, NVP Nevirapine, TDF